Most importantly, the incidence of early-stage prostate cancer found in PSA-based mass screening was high and PSA-screened patients had both a prolonged overall and prostate cancer-specific survival in comparison to clinically diagnosed patients. This evidence concerns the gene KLK3 and prostate carcinoma.